Intellia Therapeutics, Inc. (NTLA) shareholders
Close on Nov 18, 2026Market cap $1.37BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| ARK Investment Management LLC Joint filing with Catherine D. Wood (12.27%) | 14,207,324 | 12.27% | 13G (passive) amendment | Dec 31, 2025 |
| Catherine D. Wood Joint filing with ARK Investment Management LLC (11.10%) | 11,919,178 | 11.10% | 13G (passive) amendment | Sep 30, 2025 |
| BlackRock, Inc. | 8,453,014 | 8.20% | 13G (passive) amendment | Mar 31, 2025 |
| State Street Corporation | 7,809,060 | 5.60% | 13G (passive) | Sep 30, 2026 |
| Vanguard Portfolio Management | 6,266,007 | 5.30% | 13G (passive) | Mar 31, 2026 |
| Vanguard Capital Management | 5,945,571 | 5.03% | 13G (passive) | Mar 31, 2026 |
| Contrarius Investment Management Ltd Joint filing with Contrarius Investment Management (Bermuda) Ltd (5.50%) | 5,889,936 | 5.50% | 13G (passive) | Sep 30, 2025 |
| The Goldman Sachs Group, Inc. Joint filing with Goldman Sachs & Co. LLC (5.10%) | 5,498,262 | 5.10% | 13G (passive) | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NTLA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| ARK Investment Management LLC | 16,875,684 | 12.04% | $285.54M | +2,366,437 | 1.85% |
| BlackRock, Inc. | 15,409,023 | 11.00% | $260.72M | +3,253,217 | 0.00% |
| State Street Corp | 9,234,987 | 6.59% | $156.26M | +2,312,311 | 0.00% |
| Vanguard Portfolio Management LLC | 7,332,401 | 5.23% | $124.06M | +1,109,076 | 0.01% |
| D. E. Shaw & Co., Inc. | 6,443,323 | 4.60% | $109.02M | +715,146 | 0.05% |
| Vanguard Capital Management LLC | 6,028,586 | 4.30% | $102.00M | +944,481 | 0.00% |
| Two Sigma Investments, LP | 5,235,348 | 3.74% | $88.58M | +529,447 | 0.06% |
| FMR LLC | 4,773,034 | 3.41% | $80.76M | +2,705,812 | 0.00% |
| Ra Capital Management, L.P. | 4,526,926 | 3.23% | $76.60M | New | 0.67% |
| Regeneron Pharmaceuticals, Inc. | 3,702,995 | 2.64% | $62.65M | – | 35.35% |
| Geode Capital Management, LLC | 3,631,061 | 2.59% | $61.45M | +779,589 | 0.00% |
| Arrowstreet Capital, Limited Partnership | 3,280,760 | 2.34% | $55.51M | +1,883,517 | 0.02% |
| Sumitomo Mitsui Trust Holdings, Inc. | 2,897,529 | 2.07% | $49.03M | +924,468 | 0.03% |
| Nikko Asset Management Americas, Inc. | 2,897,529 | 2.07% | $49.03M | +924,468 | 0.63% |
| Dimensional Fund Advisors LP | 2,602,944 | 1.86% | $44.04M | +284,834 | 0.01% |
| Goldman Sachs Group Inc | 2,264,471 | 1.62% | $38.31M | +636,230 | 0.00% |
| UBS Group AG | 2,152,912 | 1.54% | $36.43M | −536,574 | 0.00% |
| Voloridge Investment Management, LLC | 2,066,356 | 1.47% | $34.96M | +454,822 | 0.15% |
| Contrarius Group Holdings Ltd | 1,955,228 | 1.40% | $33.08M | +43,389 | 1.52% |
| Jupiter Asset Management Ltd | 1,849,507 | 1.32% | $31.29M | +68,444 | 0.16% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 328 | 144M | 100.0% | 55 / 140 | 81 / 28 | 38M | 5M |
| Q1 2026 | 304 | 111M | 78.9% | 62 / 128 | 63 / 46 | 30M | 10M |
| Q4 2025 | 293 | 104M | 74.4% | 67 / 98 | 87 / 48 | 21M | 21M |
| Q3 2025 | 284 | 105M | 74.7% | 45 / 102 | 79 / 39 | 17M | 13M |
| Q2 2025 | 281 | 100M | 71.5% | 42 / 111 | 88 / 53 | 14M | 15M |
| Q1 2025 | 295 | 101M | 72.4% | 51 / 94 | 96 / 46 | 12M | 9M |
| Q4 2024 | 294 | 99M | 70.9% | 64 / 127 | 68 / 49 | 25M | 18M |
| Q3 2024 | 284 | 94M | 67.0% | 43 / 112 | 86 / 47 | 19M | 7M |
| Q2 2024 | 291 | 91M | 64.8% | 48 / 114 | 88 / 37 | 8M | 14M |
| Q1 2024 | 284 | 97M | 69.3% | 37 / 116 | 88 / 42 | 15M | 6M |
| Q4 2023 | 293 | 88M | 63.1% | 48 / 123 | 78 / 36 | 12M | 4M |
| Q3 2023 | 285 | 80M | 57.3% | 34 / 120 | 66 / 38 | 6M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
222 funds held NTLA in Q2 2026, 73% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NTLA | Value | % of fund | As of |
|---|---|---|---|---|---|
| ARK Innovation ETF | 9,987,315 | 7.13% | $106.66M | 1.92% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 5,756,463 | 4.11% | $97.40M | 0.91% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,286,200 | 3.06% | $72.52M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,524,614 | 2.52% | $59.64M | 0.07% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,106,242 | 2.22% | $52.56M | 0.03% | Jun 30, 2026 |
| ARK Genomic Revolution ETF | 2,667,062 | 1.90% | $28.48M | 1.83% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 1,914,833 | 1.37% | $26.94M | 0.51% | May 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,798,189 | 1.28% | $30.43M | 0.06% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,604,987 | 1.15% | $27.16M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,478,652 | 1.06% | $15.79M | 0.05% | Jul 31, 2026 |
| Select Pharmaceuticals Portfolio | 1,266,200 | 0.90% | $17.82M | 1.19% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 1,264,620 | 0.90% | $21.40M | 0.15% | Jun 30, 2026 |
| iShares Biotechnology ETF | 938,715 | 0.67% | $15.88M | 0.17% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 827,498 | 0.59% | $14.00M | 0.12% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 820,243 | 0.59% | $8.76M | 0.39% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John M. Leonard | President and CEO, Director | 1,196,479 | 0.85% | Nov 3, 2026 |
| Jing L. Marantz | EVP, Chief Medical Officer | 199,822 | 0.14% | Oct 28, 2026 |
| Michael P. Dube | VP, Chief Accounting Officer | 65,022 | 0.05% | Oct 6, 2026 |
| Edward J. Dulac III | EVP, Chief Financial Officer | 148,175 | 0.11% | Jul 24, 2026 |
| Birgit C. Schultes | EVP, Chief Scientific Officer | 137,733 | 0.10% | Mar 3, 2026 |
| James Basta | EVP, General Counsel | 156,794 | 0.11% | Mar 3, 2026 |
| David Lebwohl | EVP, Chief Medical Officer | 131,192 | 0.09% | Mar 3, 2026 |
| Eliana Clark | EVP, Chief Technical Officer | 93,864 | 0.07% | Mar 3, 2026 |
| Derek Hicks | EVP, Chief Business Officer | 59,878 | 0.04% | Jan 7, 2025 |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | 77,388 | 0.06% | Jan 7, 2025 |
| Brian Goff | Director | 32,609 | 0.02% | Jun 10, 2026 |
| Muna Bhanji | Director | 36,403 | 0.03% | Jun 10, 2026 |
| Georgia Keresty | Director | 41,083 | 0.03% | Jun 10, 2026 |
| Fred E. Cohen | Director | 216,653 | 0.15% | Jun 10, 2026 |
| Frank Verwiel | Director | 35,148 | 0.03% | Jun 10, 2026 |
| Jesse Goodman | Director | 33,559 | 0.02% | Jun 10, 2026 |
| William J. Chase | Director | 143,893 | 0.10% | Jun 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John M. Leonard President and CEO, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −9,000 | $11.99 | $107.91K | 1,138,064 |
| Jing L. Marantz EVP, Chief Medical Officer | Oct 26, 2026 | Award | +199,822 | – | – | 199,822 |
| Michael P. Dube VP, Chief Accounting Officer | Oct 2, 2026 | Sale | −1,864 | $12.43 | $23.17K | 65,022 |
| John M. Leonard President and CEO, Director | Aug 21, 2026 | Sale(10b5-1 plan) | −2,785 | $13.00 | $36.21K | 1,147,064 |
| John M. Leonard President and CEO, Director | Aug 20, 2026 | Sale(10b5-1 plan) | −19,890 | $12.60 | $250.61K | 1,149,849 |
| Edward J. Dulac III EVP, Chief Financial Officer | Jul 22, 2026 | Sale | −8,111 | $11.25 | $91.25K | 148,175 |
| Edward J. Dulac III EVP, Chief Financial Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −4,677 | $18.00 | $84.19K | 156,286 |
| Michael P. Dube VP, Chief Accounting Officer | Jul 1, 2026 | Sale | −2,641 | $16.78 | $44.32K | 66,886 |
| Fred E. Cohen Director | Jun 9, 2026 | Award | +9,200 | – | – | 216,653 |
| Jesse Goodman Director | Jun 9, 2026 | Award | +9,200 | – | – | 33,559 |
| Brian Goff Director | Jun 9, 2026 | Award | +9,200 | – | – | 32,609 |
| Georgia Keresty Director | Jun 9, 2026 | Award | +9,200 | – | – | 41,083 |
| Frank Verwiel Director | Jun 9, 2026 | Award | +9,200 | – | – | 35,148 |
| Muna Bhanji Director | Jun 9, 2026 | Award | +9,200 | – | – | 36,403 |
| William J. Chase Director | Jun 9, 2026 | Award | +9,200 | – | – | 143,893 |
| James Basta EVP, General Counsel | Mar 2, 2026 | Sale | −1,211 | $13.78 | $16.69K | 156,794 |
| Eliana Clark EVP, Chief Technical Officer | Mar 2, 2026 | Sale | −607 | $13.78 | $8.36K | 93,864 |
| Edward J. Dulac III EVP, Chief Financial Officer | Mar 1, 2026 | Award | +61,280 | – | – | 160,963 |
| John M. Leonard President and CEO, Director | Mar 1, 2026 | Award | +156,400 | – | – | 1,169,739 |
| Birgit C. Schultes EVP, Chief Scientific Officer | Mar 1, 2026 | Award | +39,200 | – | – | 137,733 |
| James Basta EVP, General Counsel | Mar 1, 2026 | Award | +46,080 | – | – | 158,005 |
| Eliana Clark EVP, Chief Technical Officer | Mar 1, 2026 | Award | +7,353 | – | – | 94,471 |
| Michael P. Dube VP, Chief Accounting Officer | Mar 1, 2026 | Award | +17,250 | – | – | 69,527 |
| David Lebwohl EVP, Chief Medical Officer | Mar 1, 2026 | Award | +9,943 | – | – | 131,192 |
| David Lebwohl EVP, Chief Medical Officer | Jan 5, 2026 | Sale | −11,903 | $9.21 | $109.63K | 121,249 |
| Michael P. Dube VP, Chief Accounting Officer | Jan 5, 2026 | Sale | −2,989 | $9.21 | $27.53K | 52,277 |
| Edward J. Dulac III EVP, Chief Financial Officer | Jan 5, 2026 | Sale | −6,379 | $9.21 | $58.75K | 99,683 |
| James Basta EVP, General Counsel | Jan 5, 2026 | Sale | −10,397 | $9.21 | $95.76K | 101,528 |
| John M. Leonard President and CEO, Director | Jan 5, 2026 | Sale | −34,146 | $9.21 | $314.48K | 1,013,339 |
| Fred E. Cohen Director | Jan 5, 2026 | Buy | +150,000 | $9.35 | $1.40M | 207,453 |
| Eliana Clark EVP, Chief Technical Officer | Jan 5, 2026 | Sale | −9,515 | $9.21 | $87.63K | 87,118 |
| Birgit C. Schultes EVP, Chief Scientific Officer | Jan 5, 2026 | Sale | −8,508 | $9.21 | $78.36K | 98,533 |
| John M. Leonard President and CEO, Director | Dec 12, 2025 | Option exercise | +8,557 | $6.83 | $58.44K | 1,047,485 |
| John M. Leonard President and CEO, Director | Dec 11, 2025 | Sale(10b5-1 plan) | −49,959 | $9.49 | $474.11K | 1,077,115 |
| John M. Leonard President and CEO, Director | Dec 11, 2025 | Sale(10b5-1 plan) | −32,832 | $9.47 | $310.92K | 1,044,283 |
| John M. Leonard President and CEO, Director | Dec 11, 2025 | Sale(10b5-1 plan) | −5,355 | $9.59 | $51.35K | 1,038,928 |
| John M. Leonard President and CEO, Director | Dec 11, 2025 | Option exercise | +49,959 | $6.83 | $341.22K | 1,127,074 |
| Michael P. Dube VP, Chief Accounting Officer | Oct 1, 2025 | Sale | −1,871 | $17.38 | $32.52K | 55,266 |
| Birgit C. Schultes EVP, Chief Scientific Officer | Oct 1, 2025 | Sale | −31 | $17.38 | $539 | 105,184 |
| William J. Chase Director | Aug 20, 2025 | Buy | +100,000 | $10.03 | $1.00M | 134,693 |
| Edward J. Dulac III EVP, Chief Financial Officer | Jul 23, 2025 | Sale | −7,462 | $14.02 | $104.62K | 106,062 |
| Michael P. Dube VP, Chief Accounting Officer | Jul 2, 2025 | Sale | −2,503 | $9.95 | $24.90K | 57,137 |
| Eliana Clark EVP, Chief Technical Officer | Jul 1, 2025 | Sale | −1,022 | $9.82 | $10.04K | 95,369 |
| Jesse Goodman Director | Jul 1, 2025 | Sale(10b5-1 plan) | −1,547 | $9.23 | $14.28K | 24,359 |
| Jesse Goodman Director | Jun 30, 2025 | Sale(10b5-1 plan) | −1,547 | $9.56 | $14.79K | 25,906 |
| Georgia Keresty Director | Jun 11, 2025 | Award | +8,000 | – | – | 31,883 |
| Fred E. Cohen Director | Jun 11, 2025 | Award | +8,000 | – | – | 57,453 |
| Jesse Goodman Director | Jun 11, 2025 | Award | +8,000 | – | – | 27,453 |
| Muna Bhanji Director | Jun 11, 2025 | Award | +8,000 | – | – | 27,203 |
| William J. Chase Director | Jun 11, 2025 | Award | +8,000 | – | – | 34,693 |
| Brian Goff Director | Jun 11, 2025 | Award | +8,000 | – | – | 23,409 |
| Frank Verwiel Director | Jun 11, 2025 | Award | +8,000 | – | – | 25,948 |
| Muna Bhanji Director | Apr 29, 2025 | Sale(10b5-1 plan) | −265 | $8.50 | $2.25K | 19,203 |
| James Basta EVP, General Counsel | Mar 4, 2025 | Sale | −2,572 | $8.99 | $23.12K | 111,925 |
| Eliana Clark EVP, Chief Technical Officer | Mar 4, 2025 | Sale | −679 | $8.99 | $6.10K | 95,369 |
| James Basta EVP, General Counsel | Mar 1, 2025 | Award | +40,000 | – | – | 114,497 |
| Edward J. Dulac III EVP, Chief Financial Officer | Mar 1, 2025 | Award | +47,200 | – | – | 113,524 |
| Eliana Clark EVP, Chief Technical Officer | Mar 1, 2025 | Award | +32,000 | – | – | 96,048 |
| John M. Leonard President and CEO, Director | Mar 1, 2025 | Award | +136,000 | – | – | 1,077,115 |
| Birgit C. Schultes EVP, Chief Scientific Officer | Mar 1, 2025 | Award | +37,600 | – | – | 105,215 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Intellia Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 399,250 shares on Sep 30, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| John M. Leonard Officer, Director | Nov 2, 2026 | 9,000 | $113.40K | Nov 2, 2026 | Stock Option Exercise |
| Eliana Clark Officer | Oct 5, 2026 | 57,750 | $736.31K | Oct 5, 2026 | Stock Option Exercise |
| John M. Leonard Officer, Director | Aug 20, 2026 | 22,675 | $293.64K | Aug 20, 2026 | Stock Option Exercise |
| Edward J. Dulac III Officer | Jul 2, 2026 | 4,677 | $80.63K | Jul 2, 2026 | Restricted Stock Units |
| John M. Leonard Officer, Director | Dec 11, 2025 | 88,146 | $822.40K | Dec 11, 2025 | Restricted Vesting |
| Laura Sepp-Lorenzino Officer | Jan 8, 2024 | 2,275 | $64.11K | Jan 8, 2024 | Restricted Stock Unit |
| John F. Crowley Former Director | Dec 7, 2023 | 32,791 | $506.70K | Dec 6, 2023 | Option Exercise |
| Muna Bhanji Director | Jul 31, 2023 | 265 | $11.22K | Jul 31, 2023 | Restricted Stock |
| Muna Bhanji Director | Jul 6, 2023 | 1,867 | $73.38K | Jul 6, 2023 | Restricted Stock |
| Eliana Clark Officer | Jun 20, 2023 | 5,000 | $225.00K | Jun 20, 2023 | Stock Option Exercise |
Congress trades
10 trades in Intellia Therapeutics reported by 2 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Donald Sternoff Beyer Jr VA08 · joint account | Sold | Feb 28, 2022 | $15K | Mar 3, 2022 |
| Donald Sternoff Honorable Beyer Jr VA08 · joint account | Sold | Oct 29, 2021 | $1K–15K | Oct 30, 2021 |
| Donald Sternoff Honorable Beyer Jr VA08 · joint account | Sold | Sep 20, 2021 | $1K–15K | Oct 1, 2021 |
| Donald Sternoff Honorable Beyer Jr VA08 · joint account | Sold | Jul 21, 2021 | $1K–15K | Aug 7, 2021 |
| Donald Sternoff Honorable Beyer Jr VA08 · joint account | Sold | Jan 15, 2021 | $1K–15K | Jan 31, 2021 |
| Donald Sternoff Beyer Jr VA08 · joint account | Bought | Nov 18, 2020 | $1K–15K | Dec 1, 2020 |
| Donald Sternoff Beyer Jr VA08 · joint account | Sold | Aug 26, 2020 | $1K–15K | Sep 6, 2020 |
| Donald Sternoff Beyer Jr VA08 · joint account | Bought | Jul 10, 2020 | $1K–15K | Aug 9, 2020 |
| Donald Sternoff Beyer Jr VA08 · joint account | Bought | Jan 14, 2020 | $1K–15K | Feb 22, 2020 |
| Donald Sternoff Beyer Jr VA08 · joint account | Bought | Dec 9, 2019 | $1K–15K | Dec 14, 2019 |
See a number that looks wrong?